What is Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of dopamine, norepinephrine, and serotonin. Originally developed as a potential treatment for neurological conditions, researchers discovered its remarkable weight loss properties during clinical trials.
Triple Action
Unlike traditional weight loss medications that target a single pathway, tesofensine simultaneously affects three key neurotransmitter systems.
Proven Efficacy
Clinical studies have demonstrated significant weight loss, with some patients achieving 8-10% body weight reduction within 6 months.
Research and Potential Benefits
Tesofensine's unique mechanism simultaneously targets three critical neurotransmitter systems for comprehensive appetite and metabolic control.
- D Dopamine: Reduces food cravings and compulsive eating by enhancing reward pathway signaling.
- N Norepinephrine: Increases metabolic rate and energy expenditure through sympathetic nervous system activation.
- S Serotonin: Enhances satiety signals and reduces emotional eating patterns.
Clinical trials demonstrate tesofensine's superior efficacy compared to traditional weight loss medications.
- ✓ Significant Results: Average weight loss of 8-10% body weight in 6-month trials.
- ✓ Dose-Dependent: Higher efficacy observed with 0.5mg and 1.0mg doses compared to 0.25mg.
- ✓ Sustained Effect: Weight loss maintained throughout treatment duration with continued benefits.
Tesofensine is a research compound requiring careful medical supervision and patient monitoring.
- ! Research Compound: Not FDA-approved; available only through specialized research protocols.
- ! Cardiovascular Monitoring: Requires blood pressure and heart rate monitoring due to norepinephrine effects.
- ! Sleep Considerations: May affect sleep patterns; typically dosed in the morning to minimize insomnia.
References & Citations
- Astrup, A., et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. The Lancet, 372(9653), 1906-1913. Source.
- Sjödin, A., et al. (2010). Randomised trial on protein vs carbohydrate in ad libitum fat reduced diet for the treatment of obesity. International Journal of Obesity, 34(8), 1243-1254. Source.
Ask Dr. John About Tesofensine
Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about Tesofensine and receive evidence-based answers from his extensive clinical experience.